Clinical trials
Locally Advanced or Metastatic Solid Tumors clinical trials
Below are recruiting locally advanced or metastatic solid tumors clinical trials, each written for real people, not researchers. We’re tracking 3,338 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05984485RecruitingPhase 3
Surgery vs chemo before surgery for low-risk rectal cancer
This trial compares two approaches for low-risk locally advanced rectal cancer: going straight to surgery (TME) versus receiving chemotherapy before surgery. The goal is to see if upfront surgery works just as well, sparing patients from chemotherapy side effects.
Chongqing, Chongqing MunicipalityAges 18–75 - NCT05600127RecruitingPhase 2
Chemotherapy then immunotherapy plus surgery for advanced bladder cancer
This Phase 2 study tests giving standard chemotherapy first, then immunotherapy, followed by major surgery to remove the bladder/urinary tumor and nearby lymph nodes. It’s for people with locally advanced urothelial cancer whose cancer has at least not worsened after initial chemotherapy.
Nijmegen, GelderlandAges 18 years+ - NCT06026878RecruitingPhase 3
GNT induction treatment for advanced nasopharyngeal cancer
This trial tests a new drug combination called GNT given before standard chemoradiation for people with locally advanced nasopharyngeal cancer. It aims to improve treatment outcomes.
Xi'an, ShaanxiAges 18–75 - NCT03742687Recruiting
Testing a shorter, stronger radiation schedule for lung cancer
This trial studies a different way to deliver radiation to people with locally advanced, non-operable non-small cell lung cancer. It may help by aiming to treat the tumor effectively with a different radiation timing and dose pattern.
AarhusAges 18 years+ - NCT05450029RecruitingPhase 2
Adding immunotherapy to chemo-radiation for rectal cancer
This Phase 2 trial studies whether adding sintilimab (an immunotherapy drug) to standard chemo-radiation before surgery can improve outcomes for people with locally advanced rectal cancer. It’s aimed at tumors with certain immune “signature” scores and specific cancer stage features.
Guangzhou, GuangdongAges 18–75 - NCT06055738RecruitingPhase 2
Zimberelimab with chemo before surgery for cervical cancer
This trial tests a combination of immunotherapy (zimberelimab) and chemotherapy before surgery for locally advanced cervical cancer that has not spread far. It aims to shrink the tumor to make surgery more effective.
Xi'an, ShaanxiAges 18 years+ - NCT03964753RecruitingPhase 2
Chemo before surgery for middle-lower esophageal cancer
This trial tests a chemotherapy combination (nab-paclitaxel plus cisplatin) given before surgery for locally advanced, operable esophageal squamous cell cancer. It aims to shrink the tumor and improve outcomes by treating cancer earlier while it’s still in one region.
Shijiazhuang, HebeiAges 18–75 - NCT05406856Recruiting
Adaptive proton therapy for cervical cancer with chemo
This trial tests whether an “adaptive” type of radiation planning using proton therapy and MRI-guided brachytherapy can improve treatment for people with cervical cancer. It aims to deliver curative treatment more precisely while still combining it with chemotherapy (cisplatin) when appropriate.
LeidenAges 18 years+ - NCT06102395RecruitingPhase 3
Pembrolizumab plus chemo before surgery for advanced head and neck cancer
This trial tests whether adding pembrolizumab (an immunotherapy drug) to standard chemotherapy before surgery can help people with advanced head and neck cancer. It aims to see if the combination is more effective than chemotherapy alone.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06074692RecruitingPhase 2
PARP inhibitor, SBRT, and immunotherapy for advanced sarcoma
This trial tests a combination of a PARP inhibitor drug, targeted radiation (SBRT), and immunotherapy for people with advanced sarcoma that has spread. It aims to see if this triple therapy can shrink tumors or slow the disease.
Shanghai, Shanghai MunicipalityAges 10–70 - NCT06125080RecruitingPhase 2
Study of utidelone plus tirelizumab and bevacizumab for advanced triple-negative breast cancer
This trial is testing a combination of three drugs (utidelone, tirelizumab, and bevacizumab) for people with advanced or metastatic triple-negative breast cancer that has not responded to at least one prior chemotherapy. The goal is to see if this combination can shrink tumors or slow the disease.
Wuhan, HubeiAges 18–70 - NCT06147570RecruitingPhase 2
Study of HS-10365 for RET fusion-positive lung cancer
This trial tests an experimental drug called HS-10365 for people with advanced or metastatic non-small cell lung cancer that has a specific genetic change called a RET fusion. The drug aims to block the growth of cancer cells with this mutation.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT05424159Recruiting
Carbon ion radiation for locally advanced pancreatic cancer
This trial tests a type of radiation that uses carbon ions to treat pancreatic cancer that can’t be removed with surgery but has not spread to distant organs. It may help shrink or control the tumor while limiting radiation side effects to nearby organs.
ShanghaiAges 18–80 - NCT06160596Recruiting
Understanding long-term cancer survival in hard-to-treat tumors
This study looks at why some people with hard-to-treat cancers live much longer than expected. It collects tumor samples to search for clues that might help future patients.
VillejuifAges 18 years+ - NCT04134780Recruiting
Ultrasound tests to spot early breast cancer treatment response
This study uses special ultrasound imaging (and may use MRI results) to look for early signs of how locally advanced breast cancer responds to chemotherapy, with or without radiation. If the imaging changes early, it could help doctors adjust treatment sooner.
Houston, TexasAges 18 years+ - NCT05833594Recruiting
Immunonutrition plus chemoradiation for unresectable esophageal cancer
This trial studies whether adding an “immunonutrition” nutrition plan to standard chemoradiation can improve outcomes for people with locally advanced, unresectable esophageal squamous cell cancer. It may help the treatment work better by supporting the immune system during therapy.
HefeiAges 18–85 - NCT05140746Recruiting
Predicting how well chemotherapy works before stomach surgery
This study looks for ways to predict whether neoadjuvant chemotherapy (chemo given before surgery) will work well in people with locally advanced stomach cancer. It may help doctors choose the best treatment plan sooner based on your test results.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT05872685RecruitingPhase 2
Perioperative chemo plus serplulimab for specific stomach cancers
This Phase 2 trial tests whether adding serplulimab (an immune medicine) to standard chemotherapy before and/or around surgery can improve outcomes for people with certain locally advanced stomach cancer. You may get serplulimab or a placebo, and researchers will compare results to see if the immune add-on helps.
Hangzhou, ZhejiangAges 18–80 - NCT07867392RecruitingPhase 2
New drug combo before surgery for stomach cancer
This study tests a combination of two immunotherapy drugs plus chemotherapy before surgery for people with locally advanced stomach or gastroesophageal junction cancer. The goal is to see if this treatment can shrink the tumor and improve outcomes.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06208917RecruitingPhase 3
Comparing two ways to give ondansetron for chemo nausea in kids
This trial compares two forms of ondansetron (a nausea medicine) — a dissolving film you put in the mouth versus a needle injection — to see which works better in preventing nausea and vomiting caused by chemotherapy in children with solid tumors.
Guangzhou, GuangdongAges 6 months–18 years - NCT06215950RecruitingPhase 1
CAR-T cell therapy for advanced gynecologic cancer with CD70 protein
This trial tests a new treatment called CAR-T cells that target a protein called CD70 found on some gynecologic cancer cells. It is for people whose cancer has advanced or spread and has not responded to or stopped responding to standard treatments.
Wuhu, AnhuiAges 18 years+ - NCT06234137Recruiting
Chemo plus targeted therapy for advanced HER2+ breast cancer
This trial tests a combination of chemotherapy (docetaxel and carboplatin) plus two targeted drugs (Inetetamab and Pyrotinib) for people with locally advanced HER2-positive breast cancer that has not spread to other parts of the body. The goal is to see if this powerful combo can shrink the tumor before surgery or other treatments.
Wenzhou, ZhejiangAges 18–75 - NCT06229041RecruitingPhase 3
Chemo and radiation with or without immunotherapy for high-risk rectal cancer
This trial tests if adding immunotherapy to standard chemotherapy and radiation before surgery helps shrink high-risk rectal cancer and prevent it from coming back. You may be a good fit if you have a specific type of advanced rectal cancer that hasn't spread to other parts of your body.
BeijingAges 18–75 - NCT06342167RecruitingPhase 2
Immunotherapy and radiation with nutrition support for esophageal cancer
This trial combines an immunotherapy drug (a PD-1 inhibitor) with radiation therapy and special nutrition drinks to treat esophageal cancer that cannot be removed with surgery. The goal is to see if this combination is safe and effective in helping patients live longer and feel better.
Beijing, Beijing MunicipalityAges 18–80
Hear when a new Locally Advanced or Metastatic Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for locally advanced or metastatic solid tumors?
- Yes. Clin2 currently lists 3,338 recruiting locally advanced or metastatic solid tumors studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a locally advanced or metastatic solid tumors trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a locally advanced or metastatic solid tumors trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Locally Advanced (Unresectable) or Metastatic Solid Tumors
- Locally Advanced/Metastatic Solid Tumors
- Advanced or Metastatic Solid Tumors
- Advanced/Metastatic Solid Tumors
- Locally Advanced or Metastatic Breast Cancer
- Locally Advanced Solid Tumor
- Locally Advanced Malignant Solid Neoplasm
- Locally Advanced or Metastatic Non-small Cell Lung Cancer
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.